Le Lézard
Classified in: Health
Subjects: NPT, TDS, FVT

MTF Biologics Launches Large FlexHD Pliable Perforated for Pre-Pectoral Breast Reconstruction



EDISON, N.J., Oct. 6, 2017 /PRNewswire/ -- MTF Biologics is unveiling its latest innovation in breast reconstruction: a new, larger size of its FlexHD Pliable Perforated acellular dermal matrix (ADM). Created in response to requests from plastic surgeons, the ADM is designed for use in pre-pectoral breast reconstruction. The larger FlexHD Pliable will be introduced at Plastic Surgery The Meeting, which is taking place October 6-10, 2017, in Orlando, Fla. 

MTF Biologics (PRNewsfoto/MTF Biologics)

"FlexHD Pliable was designed exclusively for breast reconstruction in partnership with plastic surgeons and has been continuously refined to meet their needs," said Tom Shaffer, Executive Vice-President, Global Sales & Marketing at MTF Biologics. "This new option, the largest ADM for breast reconstruction, was created specifically for the growing number of surgeons performing pre-pectoral breast reconstruction procedures. It is an example of MTF Biologics' commitment to the surgeons and patients we serve and our dedication to innovation that saves and heals lives."

FlexHD Pliable is the most innovative ADM available. It reflects MTF Biologics' three-decade legacy of driving advances in the science of tissue transplantation. It is the only ADM that uses MTF Biologics' patented deep-cut method. This method takes donated tissue from deep in the dermis, creating an ADM with consistent thickness and no sidedness that enables easier cell adhesion and incorporation. FlexHD Pliable also is elastic, pliable and conformable, with exceptional handling in the operating room. 

A driver of new standards in breast reconstruction, FlexHD was the first prehydrated ADM, making it a more convenient choice for surgeons. It also was the first ADM available in bi-lateral breast kits from the same donor in the same thickness, which may reduce complication risks for patients.  

FlexHD Pliable has been proven safe and effective for breast reconstruction and receives high patient satisfaction ratings. Published studies have shown that it has a low complication rate for issues such as infection, seroma, reconstruction failure, hematoma, and delayed wound healing that is on par with or better than other ADMs on the market.

The large FlexHD Pliable Perforated ADM will be shown at MTF Biologics' booth, #301, at Plastic Surgery The Meeting.  It also will be discussed at the Satellite Symposium, "Building a Better Breast Through Innovative Pre-Pectoral Techniques," with Dr. Garrett Wirth and Dr. Aldona Spiegel on Saturday, October 7, from 12:30-1:30 p.m. in the Orange County Convention Center, S. Concourse, Destination Lounge.

Other innovations MTF Biologics will be showcasing at Plastic Surgery The Meeting include:

About MTF Biologics
MTF Biologics, formerly Musculoskeletal Transplant Foundation (MTF), is a nonprofit organization based in Edison, N.J. It is a national consortium comprised of leading organ procurement organizations, tissue recovery organization and academic medical institutions, and governed by a board of surgeons who are leading experts in tissue transplantation. As the world's largest tissue bank, MTF Biologics saves and heals lives by honoring donated gifts, serving patients and advancing science. Since its inception in 1987, the organization has received tissue from more than 120,000 donors and distributed more than 7.5 million allografts for transplantation. Through its IIAM subsidiary, it has placed more than 55,000 non-transplantable organs for research. Through its Statline subsidiary, it has managed more than 10 million donor referrals. For more information, visit www.mtf.org.

 

SOURCE MTF Biologics


These press releases may also interest you

at 09:30
Cannabics Pharmaceuticals Inc. , a leader in personalized cannabinoid medicine focused on Cancer and its side effects, today announced that Dr. Gil Bar-Sela is scheduled to present his findings at the 3rd International Medical Cannabis...

at 09:30
Mylan N.V. and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Fulphila®, a biosimilar to...

at 09:30
SALT LAKE CITY, Sept. 21, 2018 /PRNewswire-PRWeb/ -- Today, Leavitt Risk Partners announced that the firm will be launching the BLISCare Outcome-Based Performance Guarantee at the MedTech Conference, held September 24-26 in Philadelphia, PA. This new...

at 09:29
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA")  is proud to announce that our CSO, Dr. Deanna Dryhurst, has been selected as part of The CDRD Academy's Executive Institute inaugural cohort. The 10 month, focused, executive development...

at 09:15
Puration, Inc. (USOTC: PURA) ("PURA") today announced executing a letter of intent ("LOI") to spinoff its cannabis cultivation business. The prospective "spinoff" will be affected by selling the cannabis cultivation business to a target publicly...

at 09:15
JOOL Health today announced a new partnership to bring JOOL's groundbreaking solution to the faculty and staff of the University of Delaware. JOOL is a digital personal life coach that improves overall employee well-being and organizational...




News published on 6 october 2017 at 07:00 and distributed by: